# Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

> **NCT06525246** · PHASE1 · COMPLETED · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 78 (actual)

## Conditions studied

- Stage IIIB Non-small Cell Lung Cancer
- Stage IIIC Non-Small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer
- Recurrent Non-Small Cell Lung Cancer
- EGFR Mutation-Related Tumors

## Interventions

- **DRUG:** ONO-7475
- **DRUG:** Osimertinib Mesylate

## Key facts

- **NCT ID:** NCT06525246
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-06
- **Primary completion:** 2025-06-23
- **Final completion:** 2025-06-23
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06525246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06525246, "Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06525246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*